Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits

Atherosclerosis

Volumn 142, Issue 2, 1999, Pages 345-353

  Shiomi, Masashi ^a   Ito, Takashi ^a   Tsukada, Toyohiro ^b   Tsujita, Yoshio ^c   Horikoshi, Hiroyoshi ^c  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sanraku Hospital   (Japan)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

Atherosclerosis; Combination treatment; HMG CoA reductase inhibitor; Insulin resistance improving agent; Pravastatin; Troglitazone; WHHL rabbits

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOSE RESPONSE; DRUG MIXTURE; DRUG POTENTIATION; FEMALE; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; THORACIC AORTA; XANTHOMATOSIS;

EID: 0032913601     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00259-7     Document Type: Article

References (32)

1. Yalow R.S., Berson S.A. Plasma insulin concentrations in nondiabetic and early diabetic subjects: determination by a new sensitive immunoassay technique. Diabetes. 9:1969;254-260.
2. Perley M.J., Kipnis D.M. Plasma insulin response to oral and intravenous glucose: studies in normal and diabetic subjects. J. Clin. Invest. 46:1967;1954-1962.
3. Laakso M. Insulin resistance and coronary heart disease. Curr. Opinion. Lipidol. 7:1996;217-226.
4. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 37:1988;1549-1558.
5. Lee M.K., Phillip D.G., Khoursheed M., Gao K.M., Moosa A.R., Olefaky J.M. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 43:1994;1435-1439.
6. Zhang B., Saku K., Arakawa K. Quantification of the effects of troglitazone on insulin sensitivity and, B-cell function in Watanabe heritable hyperlipidemic rabbits: a minimal model analysis. Metabolism. 46:1997;273-281.
7. Iwamoto Y., Kuzuya T., Matsuda A., Awata T., Kumakura S., Inooka G., Shiraishi I. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes. Care. 14:1991;1083-1086.
8. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331:1994;1188-1193.
9. Law RE, Meehan WP, Xi X-P, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-1905.
10. Yoshioka T., Fujita T., Kanai T., Aizawa Y., Kurumada T., Hasegawa K., Horikoshi H. Studies on hindered phenols and analogues 1: hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem. 32:1989;421-428.
11. Noguchi N., Sakai H., Kato Y., Tsuchiya J., Yamamoto Y., Niki E., Horikoshi H., Kodama T. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis. 123:1996;227-234.
12. Watanabe Y., Ito T., Shiomi M., Tsujita Y., Kuroda M., Arai M., Fukami M., Tamura A. Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim. Biophys. Acta. 960:1988;294-302.
13. Shiomi M., Ito T., Watanabe Y., Tsujita Y., Kuroda M., Arai M., Fukami M., Fukushige J., Tamura A. Suppression of established atherosclerosis and xanthoma in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Atherosclerosis. 83:1990;69-80.
14. Shiomi M., Ito T., Tsukada T., Yata T., Watanabe Y., Tsujita Y., Fukami M., Fukushige J., Hosokawa T., Tamura A. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler. Thromb. Vasc. Biol. 15:1995;1938-1944.
15. Zhang B., Saku K., Hirata K., Liu R., Tateishi K., Yamamoto K., Arakawa K. Insulin resistance observed in WHHL rabbits. Atherosclerosis. 91:1991;277-278.
16. Zhang B., Saku K., Hirata K., Liu R., Tateishi K., Shiomi M., Arakawa K. Quantitative characterization of insulin-glucose response in Watanabe heritable hyperlipidemic and cholesterol-fed rabbits and the effect of cilazapril. Metabolism. 43:1994;360-366.
17. Shiomi M., Ito T., Shiraishi M., Watanabe Y. Inheritability of atherosclerosis and the role of lipoproteins as risk factors related to coronary atherosclerosis in WHHL rabbits: risk factors related to coronary atherosclerosis are different from those related aortic atherosclerosis. Atherosclerosis. 96:1992;43-52.
18. Tsujita Y., Kuroda M., Shimada Y., Tanzawa K., Arai M., Kaneko I., Tanaka M., Masuda H., Tarumi C., Watanabe Y., Fujii S. CS-514, a competitive inhibitor of, 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibitor of sterol synthesis and hypolipidemic effect on various animal species. Biochim. Biophys. Acta. 877:1986;50-60.
19. Horikoshi H., Yoshioka T., Kawasaki T., Nakamura K., Matsunuma N., Yamaguchi K., Sasahara K. Troglitazone (CS-045) a new antidiabetic drug. Annu. Rep. Sankyo. Res. Lab. 46:1994;1-57.
20. Tsukada T., Tippens D., Gordon D., Ross R., Gown A.M. HHF35, a muscle actin-specific monoclonal antibody I: immunocytochemical and biomedical characterization. Am. J. Pathol. 126:1987;51-69.
21. Tsukada T, Rosenfeld ME, Ross R, Gown AM. Immunocytochemical analysis of cellular components in atherosclerotic lesions: use of monoclonal antibodies with Watanabe and fat-fed rabbit. Arteriosclerosis 1986;601-613.
22. Shiomi M., Ito T., Tsukada T., Yata T., Ueda M. Cell composition of coronary and aortic atherosclerotic lesions in WHHL rabbits differs: an immunohistochemical study. Arterioscler. Thromb. 14:1994;931-937.
23. Peuler J.D., Phare S.M., Iannucci A.R., Hodorek M.J. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am. J. Hypertens. 9:1996;188-192.
24. Graf K, Xi X-P, Hsueh WA, Law RE. Troglitazone inhibits angiotensin II induced DNA synthesis and migration in vascular smooth muscle cells. FEBS Lett 1997;400:119-121.
25. Morikang E., Benson S.C., Kurtz T.W., Pershadsingh H.A. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am. J. Hypertens. 10:1997;440-446.
26. Inoue I., Katayama S., Takahashi K., Negishi K., Miyazaki T., Sonoda M., Komoda T. Troglitazone has a scavenging effect on reactive oxygen species. Biochem. Biophys. Res. Commun. 235:1997;113-116.
27. Nakamura T., Kobayashi H., Yanagi K., Nakagawa T., Nishida M., Kihara S., Hiraoka H., Nozaki S., Funahashi T., Yamashita S., Kameda-Takemura K., Matsuzawa Y. Importance of intra-abdominal visceral fat accumulation to coronary atherosclerosis in heterozygous familial hypercholesterolaemia. Int. J. Obes. Relat. Metab. Disord. 21:1997;580-586.
28. Hallakou S., Doare L., Foufelle F., Kergoat M., Guerre-Millo M., Berthault M.F., Dugail I., Morin J., Auwerx J., Ferre P. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes. 46:1997;1393-1399.
29. DeVos P., Lefebvre A.M., Miller S.G., Guerre-Millo M., Wong K., Saladin R., Hamann L.G., Staels B., Briggs M.R., Auwerx J. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferatoractivated receptor γ J. Clin. Invest. 98:1996;1004-1009.
30. Sugden M.C., Grimshaw R.M., Lall H., Holness M.J. Regional variations in metabolic responses of white adipose tissue to food restriction. Am. J. Physiol. 267:1994;E892-899.
31. Bergo M., Olivecrona G., Olivecrona T. Diurnal rhythms and effects of fasting and refeeding on rat adipose tissue lipoprotein lipase. Am. J. Physiol. 271:1996;E1092-1097.
32. Nolan J.J., Olefsky J.M., Nyce M.R., Considine R.V., Caro J.F. Effect of troglitazone on leptin production: studies in vitro and human subjects. Diabetes. 45:1996;1276-1278.